{Reference Type}: Journal Article
{Title}: CDC27 gene expression patterns as a potential biomarker in Acute Leukemia.
{Author}: Pouriafar Y;Rostami S;Alizadghandforoush N;Barati M;Amini A;Safa M;
{Journal}: Mol Biol Rep
{Volume}: 51
{Issue}: 1
{Year}: 2024 Jul 29
{Factor}: 2.742
{DOI}: 10.1007/s11033-024-09744-7
{Abstract}: <B>BACKGROUND: </B>Treating Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) is difficult due to high relapse rates and drug resistance. Tumorigenesis is largely dependent on disruption of the cell cycle progression. While the role of Cell Division Cycle 27 (CDC27) in the anaphase-promoting complex/cyclosome is well-known, its significance in the pathophysiology of acute leukemia and its potential as a biomarker are less well understood.<BR><B>RESULTS: </B>This case-control study used samples from 100 leukemia patients (50 with ALL and 50 with AML) at Shariati Hospital in Tehran, Iran, along with 50 healthy individuals. The expression of CDC27 was analyzed using quantitative real-time PCR (RQ-PCR). Statistical analysis was done using the nonparametric Mann-Whitney U test. The results showed that AML and ALL patients had significantly higher levels of CDC27 expression compared to the control group. Although a weak correlation between CDC27 expression and hematological parameters was found, there was no significant correlation with sample type, demographics, clinical variables or prognosis.<BR><B>CONCLUSIONS: </B>This study highlights the potential of CDC27 as an oncogene, as well as a possible prognostic and diagnostic marker in acute leukemias. It suggests that CDC27 could be a valuable biomarker or therapeutic target in the treatment of AML and ALL.